Flaxseed (Linum usitatissimum) — whole seed, oil, and lignans

What it is

Flaxseed is the seed of Linum usitatissimum, an annual herbaceous plant of the Linaceae family, cultivated since at least 5000 BCE for fibre (linen) and oilseed. UK production is minor; commercial supply is dominated by Canada, Russia, and Kazakhstan. The seed itself is small, flat, and ovate, ranging from golden to brown in colour, and contains approximately 40 % oil by weight, 20–25 % protein, 28 % dietary fibre, and 6–8 % moisture.

The oil fraction is among the densest dietary sources of alpha-linolenic acid (ALA), an essential n-3 (omega-3) polyunsaturated fatty acid: ALA accounts for 50–60 % of total fatty acids in flaxseed oil. ALA is the parent n-3 fatty acid that the body partially converts via Δ-6 desaturase and elongase enzymes to eicosapentaenoic acid (EPA, ~5–10 % conversion efficiency in adults) and further to docosahexaenoic acid (DHA, much less efficient — often cited at <0.5 %). For people who avoid fish and algal oils, flaxseed is the most concentrated common dietary source of plant-derived n-3 fatty acids. Camden's Verifera entries on vegan-omega-3 and fish-oil position ALA upstream of the direct-EPA / DHA delivery routes — the conversion-efficiency limit is why ALA reduces LDL-C modestly (authorised claim) but has not shown the cardiovascular event-reduction signal seen in higher-quality EPA / DHA trials.

The seed fibre fraction includes lignans — polyphenolic compounds concentrated in the seed coat. The principal flaxseed lignan is secoisolariciresinol diglucoside (SDG), present at roughly 0.7–1.5 mg per gram of whole seed (variable by cultivar). Lignan bioavailability is microbiome-mediated: gut bacteria (notably Bacteroides, Clostridium, and Eubacterium species) hydrolyse SDG to secoisolariciresinol, which is then converted to the active enterolignans enterodiol and enterolactone. These bind oestrogen receptors α and β with low affinity (1/100 to 1/1000 the affinity of oestradiol) and exhibit both agonist and antagonist activity depending on the endogenous-oestrogen state of the tissue, making them selective oestrogen-receptor modulators (SERMs) in the broad sense. Importantly, only an estimated 30–50 % of women appear to be high-enterolactone producers; the rest convert SDG less efficiently or excrete it largely unmetabolised. This variability likely contributes to the heterogeneous trial responses observed in menopausal-symptom studies.

Lignan content is concentrated in the seed coat, so the three Camden-distinguished preparations carry different lignan loads: whole / ground seed (full lignan complement plus ALA plus fibre), cold-pressed oil (high ALA, near-zero lignans because the seed coat is excluded), and standardised lignan extract (concentrated SDG at declared percentages, typically 20–40 % SDG, with low ALA content). A consumer searching "flaxseed for menopause" needs the lignan extract or whole / ground seed; cold-pressed oil is largely irrelevant to the phytoestrogen use case. A consumer searching "flaxseed for cholesterol" can choose any of the three so long as the ≥2 g/day ALA threshold is met (which favours oil or generous ground-seed intake; lignan extracts typically deliver less ALA).

Commercial preparations vary widely in form and quality. Whole seeds keep best (lignan-protective seed coat intact) but require grinding for bioavailability. Ground seed and cold-pressed oil are the most oxidation-prone — rancid product loses ALA value and develops a fishy or paint-like smell from secondary lipid-oxidation products. UK retail product variability is significant, and the practical quality differentiators (cold-press oil, declared harvest date, light-protected packaging, peroxide-value testing, SDG % for lignan extracts) sit upstream of any health claim.

Camden's editorial position is that flaxseed remains a useful dietary ingredient with one authorised UK claim attached to the ALA fraction, a strong fibre / digestive-health pedigree from NHS general guidance, and a real but limited and heterogeneous lignan evidence base. The encyclopaedia entry deliberately separates the three forms and refuses to lump them under a single "flaxseed is good for" framing.

How it works

ALA's cholesterol-lowering mechanism (basis of the authorised UK Article 13.1 claim) operates through several converging pathways. ALA is incorporated into membrane phospholipids, shifting tissue n-3:n-6 ratios over weeks. Hepatic ALA partially elongates to EPA (5–10 % conversion in adults) and onward to DHA (<0.5 %); the resulting EPA / DHA pool modestly reduces hepatic VLDL synthesis and shifts apolipoprotein B-100 secretion downward, which lowers circulating LDL-C. Whole-seed and ground-seed flaxseed also contribute viscous soluble fibre and mucilage that sequester bile acids in the small intestine, prompting hepatic conversion of cholesterol into replacement bile acids. The combined effect is a small-but-consistent ~5–10 mg/dL reduction in LDL-C at typical supplemental doses — meaningful at the population level but smaller than statin therapy or higher-dose EPA / DHA.

The lignan mechanism is independent of the ALA pathway. SDG is hydrolysed in the colon by bacterial β-glucosidases to secoisolariciresinol, which is then converted by Eubacterium and Clostridium species via demethylation and dehydroxylation to enterodiol, and oxidised further to enterolactone. Enterolactone is the principal circulating enterolignan in humans and is the species detected in most epidemiological studies of lignan exposure. Enterolignans bind oestrogen receptors α and β with weak affinity, modulate sex-hormone-binding globulin (SHBG) levels (raising free-oestradiol scavenging capacity), inhibit aromatase in some tissue compartments, and exhibit antioxidant activity independent of oestrogen-receptor binding. In post-menopausal biology — where endogenous oestradiol is low — weak agonist activity at ER-β may provide a modest oestrogen-like signal; in pre-menopausal high-oestrogen biology, antagonist effects at ER-α predominate. This dual mechanism makes blanket "lignans raise" or "lignans lower" oestrogen statements wrong — the direction depends on the recipient's oestrogen state.

The fibre mechanism (whole / ground seed) is mucilage-and-cellulose bulk-forming. Soluble fibre (mucilage gum) holds water and increases stool weight; insoluble fibre adds bulk. The combined effect is a gentle bulk laxative — useful for the NHS-recommended 30 g/day total fibre intake target that most UK adults under-meet. Mechanism is straightforwardly mechanical, not metabolic.

A note on cyanogenic glycosides: flaxseed contains small amounts of linustatin and neolinustatin (cyanogenic glycosides that can release hydrogen cyanide on enzymatic hydrolysis). At normal food intakes (≤2 tablespoons/day of ground seed) the cyanide release is well below toxic thresholds — EFSA's 2019 opinion concluded dietary exposure poses no health concern at typical intake. Heat inactivates the relevant enzymes; soaking or cooking destroys the risk. The theoretical concern only applies to very high uncooked intakes, which is impractical anyway.